136 related articles for article (PubMed ID: 10220208)
1. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304.
Heinemann L; Sinha K; Weyer C; Loftager M; Hirschberger S; Heise T
Diabet Med; 1999 Apr; 16(4):332-8. PubMed ID: 10220208
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.
Brunner GA; Sendhofer G; Wutte A; Ellmerer M; Søgaard B; Siebenhofer A; Hirschberger S; Krejs GJ; Pieber TR
Exp Clin Endocrinol Diabetes; 2000; 108(2):100-5. PubMed ID: 10826516
[TBL] [Abstract][Full Text] [Related]
3. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
5. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
6. Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion.
Hamilton-Wessler M; Ader M; Dea MK; Moore D; Loftager M; Markussen J; Bergman RN
Diabetes; 2002 Mar; 51(3):574-82. PubMed ID: 11872653
[TBL] [Abstract][Full Text] [Related]
7. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
9. Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin.
Heinemann L; Heise T; Klepper A; Ampudia J; Bender R; Starke AA
Diabete Metab; 1995 Dec; 21(6):415-9. PubMed ID: 8593922
[TBL] [Abstract][Full Text] [Related]
10. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
11. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
[TBL] [Abstract][Full Text] [Related]
12. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue.
Kurtzhals P; Havelund S; Jonassen I; Markussen J
J Pharm Sci; 1997 Dec; 86(12):1365-8. PubMed ID: 9423147
[TBL] [Abstract][Full Text] [Related]
13. [Insulin detemir (NN304)].
Kaku K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():511-5. PubMed ID: 12387043
[No Abstract] [Full Text] [Related]
14. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
Heinemann L; Weyer C; Rauhaus M; Heinrichs S; Heise T
Diabetes Care; 1998 Nov; 21(11):1910-4. PubMed ID: 9802742
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
[TBL] [Abstract][Full Text] [Related]
16. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake.
Dea MK; Hamilton-Wessler M; Ader M; Moore D; Schäffer L; Loftager M; Vølund A; Bergman RN
Diabetes; 2002 Mar; 51(3):762-9. PubMed ID: 11872677
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
18. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
19. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
20. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
